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Primary biliary cirrhosis (PBC) is an auto-
immune liver disease of middle-aged women 
characterized by a progressive portal lympho-
cytic infl ammatory response and destruction of 
intrahepatic bile duct epithelial cells. A sero-
logic hallmark of PBC is autoantibodies reac-
tive with the mitochondrial subunits of the 
2-oxoacid dehydrogenase complexes, particu-
larly the E2 subunit of the pyruvate dehydro-
genase complex (PDC-E2), which appear long 
before the clinical onset of disease (1–3). The 
epitopes recognized by anti–PDC-E2 and au-
toreactive CD4+ and CD8+ T cells map within 
the inner lipoyl domain of PDC-E2 (4–6). 
 Intriguingly, the mitochondrial PDC-E2 auto-
antigen is found in all nucleated cells in the 
body, yet the bile duct epithelial cells in which 
mitochondria are relatively sparse are the major 
target of immunodestruction. An understand-
ing of how a ubiquitous self-antigen, PDC-E2, 
becomes a focus of autoimmune reactivity, 
with damage only in the biliary system, is cen-
tral to understanding the pathogenesis of PBC. 
Hitherto, the lack of an animal model has been 
a major handicap, leading to reliance on small 
liver biopsy samples and explant livers in the 
advanced stages of disease to defi ne the immuno-
logical status of the portal triad.
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Primary biliary cirrhosis (PBC) is an autoimmune disease with a strong genetic component 
characterized by biliary ductular infl ammation with eventual liver cirrhosis. The serologic 
hallmark of PBC is antimitochondrial antibodies that react with the pyruvate dehydroge-
nase complex, targeting the inner lipoyl domain of the E2 subunit (anti–PDC-E2). Herein 
we demonstrate that NOD.c3c4 mice congenically derived from the nonobese diabetic 
strain develop an autoimmune biliary disease (ABD) that models human PBC. NOD.c3c4 
(at 9–10 wk, before signifi cant biliary pathology) develop antibodies to PDC-E2 that are 
specifi c for the inner lipoyl domain. Affected areas of biliary epithelium are infi ltrated with 
CD3+, CD4+, and CD8+ T cells, and treatment of NOD.c3c4 mice with monoclonal antibody 
to CD3 protects from ABD. Furthermore, NOD.c3c4-scid mice develop disease after adop-
tive transfer of splenocytes or CD4+ T cells, demonstrating a central role for T cells in 
pathogenesis. Histological analysis reveals destructive cholangitis, granuloma formation, 
and eosinophilic infi ltration as seen in PBC, although, unlike PBC, the extrahepatic biliary 
ducts are also affected. Using a congenic mapping approach, we defi ne the fi rst ABD (Abd) 
locus, Abd1. These results identify the NOD.c3c4 mouse as the fi rst spontaneous mouse 
model of PBC.
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Recently, we reported that the NOD.c3c4 mouse, which 
is completely protected from diabetes by B6/B10 regions on 
chromosomes 3 and 4 that contain B6/B10 insulin-depen-
dent diabetes (Idd) loci, spontaneously developed an autoim-
mune biliary ductular disease with lymphocytic infi ltrates, 
antinuclear antibodies (ANAs), and eventually fatal biliary 
obstruction (7). The disease could be transferred by spleno-
cytes to naive mice, suggesting an autoimmune etiology (7). 
The nonobese diabetic (NOD) mouse is well known as a 
model of autoimmune type 1 diabetes that results from a 
spontaneous T lymphocytic attack on pancreatic islet β cells 
(8). In addition, older NOD mice develop lymphocytic infi l-
trates at other sites, notably salivary and lacrimal glands, and 
the thyroid gland (9), but the liver is spared. Interestingly, 
NOD congenic mice bearing a non-NOD MHC region de-
velop a Sjogren’s-like syndrome (10), and a TCR transgene 
on the NOD background results in a spontaneous articular 
disease closely resembling rheumatoid arthritis (11). Collec-
tively, NOD and genetically modifi ed NOD mice (NOD 
congenics and NOD transgenics) represent a remarkable kin-
dred of genetically related mice that express the same types of 
diseases seen in kindreds of patients with PBC, particularly 
type 1 diabetes, rheumatoid arthritis, Sjogren’s syndrome, 
and thyroiditis.
We report herein several components of disease shared 
between the NOD.c3c4 and PBC, narrow the genetic inter-
vals necessary for disease, and defi ne the fi rst autoimmune 
biliary disease (ABD)-associated locus (Abd1). Our data dem-
onstrate that NOD.c3c4 mice have CD3+, CD4+, and CD8+ 
T cell infi ltrates in aff ected biliary epithelium. The CD4+ 
fraction of the NOD.c3c4 cell population produces multiple 
cytokines, and the hepatic lymphoid cell (HLC) population 
changes over the course of disease. Anti-CD3 treatment pre-
vents disease onset and NOD.c3c4-scid mice develop ABD 
after the adoptive transfer of T cells from diseased NOD.c3c4 
mice, demonstrating a pathologic role for T cells in the dis-
ease process. Finally, NOD.c3c4 mice spontaneously develop 
autoantibodies to PDC-E2 as early as day 67, well before the 
appearance of ANAs and other autoantibodies previously 
 described in NOD mice (7). Collectively, these fi ndings 
demonstrate coordinate dysregulation of both T and B cell 
responses to biliary tissue in this model, establishing this as a 
spontaneous mouse model of PBC.
RESULTS
Genetic dissection of ABD defi nes a disease causative region 
(Abd1) on chromosome 4
NOD.c3c4 mice have large chromosome 3 and chromosome 
4 B6/B10-derived regions of the genome introgressed onto 
the NOD background. Each is 80 megabases (Fig. 1). As we 
reported previously, strain 1802 develops ABD, although with 
reduced penetrance (7). Strain 1802 has the same B10 chro-
mosome 4 interval as NOD.c3c4, but a signifi cantly decreased 
chromosome 3 interval, eliminating the large region of intro-
gressed B6-derived DNA between Idd3 and Idd10/18, includ-
ing the Idd17 region (Fig. 1). We dissected the genetic regions 
on chromosome 4 necessary for disease. The 1803 mouse was 
constructed with the same interval on chromosome 3 as strain 
Figure 1. Genetic map of NOD.c3c4, 1803, and 1802 defi ning 
Abd1. Strain 1802 develops biliary disease, although at decreased pen-
etrance compared with NOD.c3c4. Strain 1803 is free from ABD and 
 differs from 1802 only on the upper portion of the chromosome 
4 segment (labeled Abd1), which is distinct from the known chromosome 
4 Idd regions.
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1802, but with a truncated interval on chromosome 4 (Fig. 1). 
Notably, strain 1803 retained the known chromosome 4 Idd 
loci 1dd9.1, 9.2, and 9.3, but was completely protected from 
ABD because none of 16 mice aged up to 50 wk had liver dis-
ease. These data defi ne an 30-megabase region of chromo-
some 4, which is both necessary for ABD and separate from 
the Idd loci necessary for autoimmune diabetes. Therefore, we 
have defi ned the fi rst ABD-specifi c locus (Abd1; Fig. 1).
Comparable liver histology in NOD.c3c4 mice and PBC
We previously identifi ed lymphocytic infi ltrates around bili-
ary epithelium in 44% of 8-wk-old and 71% of 16-wk-old 
Figure 2. Invasion by CD3+, CD4+, and CD8+ cells of NOD.c3c4 
biliary epithelium. Immunohistochemistry using anti-CD3 (a) or isotype 
control antibody (b) on NOD.c3c4 liver sections, showing CD3+ cells 
(reddish-brown) directly adjacent to biliary epithelial cells in areas of cyst 
formation, but not adjacent to hepatocytes. (c) Magnifi ed view showing 
CD3+ cells located directly adjacent to biliary epithelial cells (blue). 
(d) Control B6 liver showing lack of lymphocytic infi ltrates, 
(e) immunohistochemical staining of CD4+ T cells infi ltrating the 
peribiliary region, adjacent to cystic biliary changes, and (f) immuno-
histology of CD8+ mononuclear lymphoid cells in NOD.c3c4 mice. Note 
the presence of aggregated as well as dispersed CD8+ mononuclear cells 
(arrows) infi ltrating the portal tracts. (g) Immunohistochemical 
staining of pDCA1+ dendritic cells in the peribiliary infi ltrate. 
All bars, 50 μm.
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NOD.c3c4 mice (7). Using immunohistochemistry, we iden-
tifi ed these as predominantly CD3+ T cell infi ltrates. These 
infi ltrates were not adjacent to hepatocytes (Fig. 2, a and b), 
but rather adjacent to biliary epithelial cells (Fig. 2 c), consis-
tent with direct interaction of T cells with biliary epithelial 
cells. Further immunohistochemical analysis demonstrated 
that the peribiliary CD3+ cells were comprised of cells from 
CD4+ and CD8+ lineages (Fig. 2, e and f). Moreover, NOD.
c3c4 peribiliary regions, but not those of control strains, 
demonstrated infi ltrating pDCA1+ dendritic cells (Fig. 2 g).
Human PBC is histologically characterized by early peri-
ductular granuloma formation as well as portal eosinophilic 
infi ltrates and destruction of small hepatic ducts, called 
 nonsuppurative destructive cholangitis (NSDC; references 
12–14). Terasaki et al. (13) found that earlier eosinophilic 
 infi ltration correlated positively with peribiliary lymphoid 
infi ltrates, granuloma formation, and duct lesions. Later stages 
are marked by fi brosis and eventual cirrhosis. In this study, 
we confi rmed our previous fi ndings of anatomical abnor-
malities consisting of marked biliary polycystic disease in the 
liver in almost all 20–30-wk-old NOD.c3c4 mice (7) but 
have identifi ed novel histological fi ndings comparable to hu-
man PBC. Histologically, biliary cyst formations were found 
in the intrahepatic biliary tree, whereas bile duct damage in-
cluding NSDC-like lesions was identifi ed, primarily in the 
small intrahepatic bile ducts (Fig. 3). Specifi cally, peribiliary 
lymphocytic infi ltration and interlobular bile duct damage 
including NSDC-like lesions with macrophage aggregates 
in the lumen were found in seven out of seven NOD.
c3c4 mice, eosinophilic infi ltration and early fi brosis were 
found in two out of seven NOD.c3c4 mice, and epitheloid 
 granuloma-like lesions were found in one out of seven NOD.
c3c4 mice (Fig. 3, a–f ). In older mice (30 wk), biliary poly-
cystic changes became more prominent and may even mask 
the NSDC-like lesion.
We further analyzed the HLC population in NOD.c3c4 
mice by comparison with that of biliary disease-free NOD, 
1803, and B6.G7 mice. The composition of the HLC popula-
tions diff ered markedly from that of spleen or lymph nodes due 
to an increased percentage of NK, γ-δ T cells, and NKT cells, 
although the proportions of cell subsets in pre-disease NOD.
c3c4, NOD, and 1803 mice were comparable (Fig. 4 a). How-
ever, the HLC composition changed in NOD.c3c4 mice com-
pared with disease-free 1803 mice and young NOD mice (Fig. 
4 b). NOD.c3c4 mice developed an increased number of gran-
ulocytes (Fig. 4 b) and a decrease in the CD4/CD8 ratio from 
5 in pre-disease mice to 2 after 30 wk of age (not depicted).
Cytokine production by HLCs in NOD.c3c4 mice
To further characterize the HLCs from NOD.c3c4, we mea-
sured cytokine production and compared this with production 
by lymph node or splenic cells from the same animal (Fig. 5). 
Ribonuclease protection analysis demonstrated considerable 
production of IL-4, IL-5, IL-10, and IL-13 mRNA only in 
stimulated NOD.c3c4 HLC CD4+ cells and not in peripheral 
CD4+ lymph node cells from the same animal (Fig. 5 a). HLCs 
stimulated with anti-CD3 and anti-CD28 demonstrated abun-
dant IL-4 protein production, whereas lymph node and splenic 
cells from the same animal produced none (Fig. 5 b). To fur-
ther characterize the cellular source of HLC cytokine produc-
tion, we fractionated the total HLC population into CD4+ and 
CD8+ populations and assayed cytokine production by each 
after stimulation with anti-CD3 and anti-CD28 mAbs (Fig. 
5 c). CD4+ T cells in the HLC population were clearly the 
source of almost all IFN-γ and IL-2 production (Fig. 5 c).
Anti-CD3 treatment ameliorates disease course 
in NOD.c3c4 mice
The presence in NOD.c3c4 mice of CD3+, CD4+, and 
CD8+ T cells infi ltrating the biliary epithelium, together 
Figure 3. Histological sections of (a–c) 20- and (d–f) 30-wk-old 
NOD.c3c4 mice livers showing lesions comparable to PBC. (a) Granu-
lomatous lesion in a portal area, (b) chronic NSDC in portal area, and 
(c) peribiliary lymphoplasmacytic infi ltration. Progression of the liver 
pathology in 30-wk-old NOD.c3c4 mice is shown by (d) pronounced 
biliary polycystic changes with infi ltration of infl ammatory cells, (e) fi brosis 
in the portal areas with eosinophilic infi ltration (blue arrows), (f) hyper-
plasia of biliary epithelium with dilation of bile duct (black arrows) and 
degenerative biliary ductules with macrophage aggregates in the lumen 
(green arrows). All bars, 50 μm.
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with active cytokine production by CD4+ HLCs, suggested 
a critical role for CD3+ T cells in pathogenesis. We sought 
to confi rm this by T cell–directed immunotherapy because 
anti-CD3 antibodies prevent type 1 diabetes in NOD mice 
(15). A single injection of 200 μg anti-CD3 ameliorated dis-
ease in NOD.c3c4 mice. 3 out of 12 anti-CD3–treated 
NOD.c3c4 mice developed ABD compared with 6 out of 
8 PBS-treated mice (P = 0.028). Anti-CD3 treatment was 
 associated with a persistent, signifi cant (P = 0.04) decrease in 
the number of HLC CD69+ T cells (Fig. 6). The decreased 
number of CD69+ cells was specifi c to the HLC population, 
as splenic populations did not diff er between treated and 
control mice (Fig. 6).
Early involvement of the common bile duct (CBD): a specifi c 
predictor of disease
We obtained an additional clue to the pathogenesis of ABD 
by the surprising discovery in young NOD.c3c4 mice of in-
volvement of the CBD illustrated by comparison of the cali-
ber of the CBD and portal vein. The ratio is 1:1 in normal 
mice but considerably greater in NOD.c3c4 mice (Fig. 7). 
This unique dilation of the CBD was found in very young mice. 
Figure 4. Cellular composition of the HLC population changes 
with age in NOD.c3c4, but not strain 1803, mice. (a) The NOD.c3c4 
HLC population does not differ from that of NOD or 1803 mice before 
30 wk of age. HLCs were isolated, stained with surface markers, lympho-
cyte gated, and analyzed by FACS (see Materials and methods) from NOD, 
1803, and NOD.c3c4 mice. There was no signifi cant difference in cell 
 composition between NOD, NOD.c3c4, or 1803 mice (1803 NOD, n = 3–5; 
NOD.c3c4, n = 8–10, except in the case of γδT; NOD.c3c4, n = 4). All 
mice were 15–25 wk old. (b) Granulocyte accumulation in aged NOD.c3c4 
mice. In NOD.c3c4 and 1803 >30 wk old, HLCs were isolated and ana-
lyzed by FACS as described above, using granulocyte gates (circled areas). 
Aged NOD.c3c4 showed a signifi cantly increased accumulation of GR-1+ 
cells (41.4%) compared with aged 1803 mice (7.8%), which did not differ 
from young NOD.c3c4 mice (7.4%).
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70% of NOD.c3c4 had CBD dilation (CBDD) at 3 wk of 
age, a pathology never seen in NOD, B6.G7, 1803, or any 
other mouse that did not develop ABD. We examined 40 
NOD.c3c4 mice aged 24 wk and less. 18 out of 24 female 
and 11 out of 16 male mice in this age range demonstrated 
CBDD. To determine whether this fi nding had predictive 
power for disease, we examined 20 NOD.c3c4 mice aged 
>30 wk and 16 had CBDD. Histologically, there was a 100% 
correlation for all 16 mice between CBDD and histological 
evidence of ABD, suggesting that the extrahepatic bile duct 
lesion is an essential component in the autoimmune process. 
Histological examination of the CBD confi rmed pathological 
involvement, and, exclusively, NOD.c3c4 mice demonstrated 
thickening of the wall of the CBD, tortuous dilation, and 
a substantial subepithelial lymphocytic infi ltrate (Fig. 7 a). Nota-
bly, anti-CD3 treatment prevented these changes (Fig. 7 b).
Transfer studies further defi ne disease pathogenesis
The fi nding that CBDD is an early and highly specifi c marker 
of disease activity prompted us to perform transfer studies us-
ing CBDD as a disease phenotype that can be assessed more 
quickly than histology. We demonstrated previously that we 
could use irradiated NOD.c3c4 mice as transfer recipients 
(7). We used our newly constructed, disease-resistant 1803 
strain to test if Abd1 on hematopoietic donor cells alone was 
suffi  cient to transfer disease. We also used NOD.scid recipi-
ents to avoid irradiating the recipient mice and to test if dis-
ease could be transferred to a strain lacking the B6/B10 
disease–associated regions. We transferred 20 × 106 whole 
splenocytes from diseased NOD.c3c4 female donors into 
a total of fi ve female 1803, six female NOD-scid, and four 
positive control–irradiated female NOD.c3c4 recipients as 
described previously (7) and assessed CBDD between 5 and 
14 wk after transfer. Consistent with our previous report, 
four out of four NOD.c3c4 recipients developed disease. 
Two of the mice studied developed CBDD at 5 wk after 
transfer. In contrast, none of the six NOD.scid recipients and 
none of the fi ve 1803 recipients developed CBDD, remain-
ing disease free even 3 mo after transfer. Because the 1803 
strain lacks a B10 allele at the Abd1 region compared with 
NOD.c3c4, these results demonstrate that Abd1 expression in 
the recipient is required to induce ABD when splenocytes are 
transferred from diseased donors.
Using irradiated recipients is not ideal because radiation 
alone has a disease-modifying eff ect (7) and may alter the 
 biology of the recipient mouse. To circumvent this prob-
lem and allow detailed analysis of ABD pathogenesis, we 
developed a NOD.c3c4-scid strain and performed transfer 
studies as outlined above. None of the four NOD.c3c4-scid 
mice  receiving PBS alone developed CBDD at 4 wk after 
transfer, whereas three out of three NOD.c3c4-scid recipi-
ents receiving 20 × 106 splenocytes from diseased NOD.
c3c4 donors developed CBDD. These results confi rm the 
role of the hematopoietic system in disease pathogenesis. 
Moreover, they demonstrate that if Abd1 is expressed in 
the recipient, even in the absence of functioning lympho-
cytes,  hematopoietic cells from donors with ABD can 
transfer disease. Finally, to further narrow the subset of cells 
transferring disease, we purifi ed CD4+ cells from diseased 
NOD.c3c4 splenocytes and transferred 14 × 106 CD4+ 
cells into NOD.c3c4-scid and NOD-scid recipients. At 4 wk 
after transfer, two out of three NOD.c3c4-scid recipients 
developed CBDD, whereas none of the three NOD-scid 
 recipients showed CBDD. These  results demonstrate that 
Figure 5. Differential cytokine production from HLCs and periph-
eral tissue lymphoid cells. (a) CD4+ cells were isolated from HLCs or 
peripheral lymphoid tissue (lymph node, spleen) and stimulated with anti-
CD3/CD28 for 3 d before ribonuclease protection assay (see Materials 
and methods). Only HLC CD4+ T cells produced detectable amounts of IL-4, 
IL-5, IL-10, or IL-13. Data are representative of four separate experiments. 
(b) HLCs or peripheral lymphoid cells were stimulated for 3 d, and super-
natants were collected and assayed for IL-4 production (see Materials and 
methods). Only HLCs produced substantial amounts of IL-4. The mean + 
SEM for multiple experiments is shown (LN and HLC, n = 4 experiments; 
spleen, n = 2). (c) CD4+ cells are the source of HLC cytokines. NOD.c3c4 
HLCs were isolated as described above, purifi ed into CD4+ and CD8+ cell 
fractions, and stimulated for 3 d, with anti-CD3/CD28 and supernatants 
collected for ELISA. Only the CD4+ fraction produced measurable amounts 
of IL-2 or IFN-γ. Data are representative of four separate experiments.
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CD4+ cells alone are suffi  cient to transfer ABD to a geneti-
cally susceptible host.
NOD.c3c4 mice, in contrast to NOD, NOD.c3, or NOD.c4 
mice, develop anti–PDC-E2 at an early age
We demonstrated previously that NOD.c3c4 and NOD.c4 
mice developed autoantibodies, including ANA and anti-Sm 
(7). To test for autoantibodies characteristic of human ABD, 
we examined sera from NOD, NOD.c3, NOD.c4, and 
NOD.c3c4 mice for AMA. Negative tests were obtained for 
six out of six NOD female mice, six out of six NOD.c4 
 female mice, and six out of six NOD.c3 female mice. 
In contrast, a high proportion (10 out of 18) of female NOD.
c3c4 mice produced anti–PDC-E2 (Fig. 8). Kinetic analysis 
of PDC-E2 reactivity revealed a markedly diff erent pattern 
than that observed for ANA in NOD.c3c4 mice (Fig. 8 b). 
Serum samples from three out of fi ve female NOD.c3c4 
mice examined at 9–10 wk of age were ANA− but had anti–
PDC-E2 antibodies even though the mice did not yet have 
detectable liver lymphocytic infi ltrates histologically. At later 
time points, four out of seven female NOD.c3c4 mice tested 
at 14–20 wk of age were anti–PDC-E2+, as were three out 
of six female mice tested at 20–25 wk of age. Although ANA 
positivity developed later and persisted in NOD.c3c4 mice, 
anti–PDC-E2 developed earlier, peaked, and declined in fre-
quency with age (Fig. 8 b). To confi rm the antigenic speci-
fi city of the anti-PDC antibodies, we used two approaches. 
First, an enzymatic inhibition assay demonstrated that only 
human sera from PBC patients and NOD.c3c4 sera, not con-
trol sera, inhibited the enzymatic activity of PDC in a sub-
strate-dependent manner (Table I). Second, use of recombinant
proteins covering the major PDC-E2 domains, the inner and 
outer lipoyl domains, the E1/E3 binding site, and the cata-
lytic domain showed that NOD.c3c4 sera were reactive only 
to the PDC-E2 inner lipoyl domain, which is the site of the 
dominant epitope for human PBC sera (Table II).
DISCUSSION
The NOD.c3c4 mouse expresses a spontaneous ABD that 
provides for the fi rst time a model of human PBC. In this re-
port, we demonstrate multiple immune abnormalities specifi c 
to the NOD.c3c4 mouse: CD3+, CD4+, and CD8+ T cells 
infi ltrate the biliary epithelium in aff ected areas of the liver; 
CD4+ T cells produce excess cytokines; the composition of 
the HLC changes with age only in diseased NOD.c3c4 mice; 
Figure 6. Anti-CD3 treatment of NOD.c3c4 mice ameliorates ABD 
and decreases the number of TCR+ CD69+ cells in the HLC popula-
tion. Mice were treated with either a single dose of 200 μg anti-CD3 
antibody in PBS or PBS alone between 6–10 wk of age, and HLC 
TCR+CD69+ cells were quantitated at 12 wk after treatment. A single 
dose of anti-CD3 antibody signifi cantly reduced the number of 
TCR+CD69+ cells in the HLCs, but not in the spleen, compared with 
PBS-treated animals. Data shown are one representative of three 
separate experiments.
Table I. Inhibition of PDC enzyme activity by autoantibodies
Group % Inhibition ± SEM
AMA+ c3c4 (n = 6) 54.73 ± 10.72a
NOD (n = 6) 5.3 ± 3.2
PBC (n = 6) 63.38 ± 8.74a  
Control human 1.25 ± 0.85
aP < 0.001 when compared with NOD and control human.
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and specifi c serum autoantibody to PDC-E2 is demonstrable 
at the relatively early age of 9–10 wk. Moreover, treatment 
with anti-CD3 antibody ameliorates expression of the disease 
and decreases the number of intrahepatic CD69+ T cells. 
Finally, CD4+ cells from diseased donors are suffi  cient to 
transfer disease into NOD.c3c4-scid mice. These fi ndings 
demonstrate an essential role for T cells in the disease process. 
Genetic studies of the NOD.c3c4-related strain 1803 dem-
onstrated that there is at least one locus specifi cally required 
for the development of ABD, which we have designated 
Abd1 (Fig. 1). To have any penetrance of ABD, there must 
be a B10 allele at the Abd1 locus in addition to B6 alleles at 
loci on chromosome 3 that overlap with regions known to 
infl uence susceptibility to type 1 diabetes: Idd3, Idd10, and 
Idd18. Transfer studies into the 1803 strain demonstrate that 
the presence of Abd1 in the transferred hematopoietic cells 
is not suffi  cient to induce disease. The successful transfer of 
ABD into NOD.c3c4-scid recipients requires Abd1 to be 
expressed in at least some cells of the recipient.
We also describe a highly specifi c marker of disease that 
appears as early as 3 wk of age in NOD.c3c4 mice, but not in 
NOD, 1803, or any other mouse strain lacking ABD, namely 
CBDD, which correlated closely with histological disease. 
Microscopically, NOD.c3c4 mice show specifi c hepatic 
 lesions in portal tracts analogous to those in human PBC, 
 including epithelial granuloma-like formation, NSDC-like 
lesions, eosinophilic infi ltrates, and early fi brosis. Moreover, 
with age, the liver of NOD.c3c4 mice has an increasing 
number of granulocytes as well as a decreased CD4/CD8 
 ratio, which is signifi cant because in human PBC, myeloper-
oxidase+ cells may contribute to bile duct damage (16) and 
CD8+ cells are implicated in pathogenesis (17, 18). Finally, 
we demonstrate for the fi rst time to our knowledge sponta-
neous development at a young age (9–10 wk) of autoanti-
bodies to PDC-E2 in this mouse model. Such antibodies 
hitherto have been experimentally induced in mice but never 
observed to occur spontaneously (19). Similar to anti–PDC-
E2 activity in PBC patients, sera from NOD.c3c4 mice 
Figure 7. Dilated CBD is an early and specifi c indication of NOD.
c3c4 biliary disease and refl ects lymphocytic infi ltration. (a) Sub-
stantially dilated CBDs (CBD) compared with the portal vein (PV) are 
found only in NOD.c3c4 mice (left) with liver disease, but not in NOD mice 
(right) or any other strains in absence of biliary disease. Bars, 1.5 mm. 
CBD and PV are shown digitally cropped from surrounding tissue. 
(b) Dilated NOD.c3c4 CBDs demonstrate lymphocytic infi ltrates, tortuosity, 
and medial thickening (left). Anti-CD3 treatment (right) prevented histo-
logical abnormalities. Arrows point into the CBD lumen. Bars, 500 μm.
Figure 8. NOD.c3c4 mice develop anti–PDC-E2 antibodies at an 
early age. (a) Recombinant PDC-E2 was resolved by SDS-PAGE, trans-
ferred onto a nitrocellulose membrane, and probed with NOD.c3c4 sera 
(lanes 1 and 2); NOD.C3, NOD.C4, and NOD sera (lanes 3–5); and an mAb 
to PDC-E2 (lane 6), all at a 1:200 dilution. Reactivity was revealed by en-
hanced chemiluminescence (see Materials and methods). (b) Time course 
of NOD.c3c4 mice of anti–PDC-E2 and ANA reactivity from early age to 
200 d. Signifi cance according to Fisher’s exact test.
Table II. Epitope mapping of anti–PDC-E2
PDC-E2 domains NOD.c3c4 NOD
Outer lipoyl Negative Negative 
Inner lipoyl Positive Negative 
E1/E3 binding site Negative Negative
Catalytic domain Negative Negative
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 inhibited PDC enzyme function and reacted with an epitope 
within the inner lipoyl domain of PDC-E2. Anti–PDC-E2 
preceded the detection of histological abnormalities in the 
liver as well as the development of ANA (7), equivalent 
to the occurrence of anti–PDC-E2 in patients several years 
before the overt onset of PBC.
The results presented here raise interesting questions. 
First, how closely does this model resemble human PBC? 
The strongest and likely most important resemblance is the 
spontaneous early occurrence of autoantibodies to PDC-E2 
before the development of biliary ductular abnormalities. 
The overall prevalence of anti–PDC-E2 is less in NOD.c3c4 
mice (56%) than in humans with PBC (90–95%). Moreover, 
some mice do develop histological ABD but not anti–PDC-E2. 
However, “AMA− PBC” is well known in humans and can 
account for up to 10% of all patients with PBC. We also note 
that various mouse strains have diff erent penetrance of genes 
for autoantibody production; i.e., the MRL/Mp-lpr/lpr mice 
develop anti-Sm antibodies at a 25% incidence in a manner 
that appeared genetically controlled but stochastic (20). We 
regard the spontaneous development of anti-PDC antibodies 
as critically important, despite the lack of full penetrance, for 
several reasons. One is that an understanding of the develop-
ment of these antibodies that are so constantly associated with 
PBC should provide insights into the induction of the human 
counterpart, and may well dispel the longstanding concern 
that such antibodies are not truly disease relevant but rather 
are simply epiphenomena. Another is that the appearance of 
anti–PDC-E2 in NOD.c3c4 mice, even if not directly or in-
directly contributing to disease, points to specifi c T cell help 
for their generation. This, together with our fi nding of 
CD3+, CD4+, and CD8+ T cell infi ltration of the biliary 
 epithelium, production by CD4+ T cells of the majority of 
the proinfl ammatory cytokines, amelioration of disease by 
anti-CD3, and transfer of disease by CD4+ cells into NOD.
c3c4-scid mice, which are T and B cell defi cient, indicates a 
major T cell response to PDC-E2 in these mice as in human 
PBC (1). Detailed dissection of the T cell epitope response to 
PDC-E2 in NOD.c3c4 mice is under active investigation in 
our laboratories. Another interesting aspect of disease in 
NOD.c3c4 mice is the role of sex in disease outcome. We 
originally reported earlier mortality in females compared 
with male mice, and that female mice had higher autoanti-
body titers (7). Here we have studied this issue in much 
more detail and report that male and female NOD.c3c4 
mice develop CBDD, as well as histological evidence of 
disease that correlates very highly with CBDD, with equal 
prevalence. Moreover, male and female mice show sta-
tistically indistinguishable numbers of ANA+ mice until 
200 d old, although female mice older than 200 d may show 
a trend to a higher prevalence of ANA positivity. We 
therefore cannot conclude that the increased mortality 
originally reported for female mice is due to a greater prev-
alence of autoimmunity in these mice; e.g., male mice may 
resist the autoimmune liver disease longer because of in-
creased body weight or some other confounding factor. 
This is an interesting issue that will require further studies 
to elucidate.
A disease feature by which NOD.c3c4 ABD diff ers from 
PBC is the site of the initial autoimmune attack, the CBD 
versus intrahepatic cholangiocytes. Virtually all mice with 
ABD initially develop an abnormally dilated CBD character-
ized histologically by lymphocytic infi ltration, a feature lack-
ing in the pathology of PBC. Still, it is intriguing that this 
initial lesion results from an immune response occurring at 
the gut: CBD interface. The small intestine, pancreatic duct, 
and CBD constitute an “anatomic nexus,” and, although in 
NOD.c3c4 mice the pathology swings from the CBD to the 
intrahepatic biliary ducts as the disease progresses, in NOD 
and (NOD×NOD.c3c4)F1 mice the disease process is foc-
used on the pancreas and pancreatic islets. Does a genetically 
controlled diff erence between these related strains modulate 
the early immune response in the gut, whether based on 
 innate or adaptive immunity, to determine the anatomical 
“switchpoint” resulting in one syndrome or another? Because 
hyperresponsiveness of B cells to a Toll-like receptor stimu-
lus has been shown in humans with PBC (21), the early B cell 
response in NOD.c3c4 mice is a priority in our laboratories. 
Notably, one of the handicaps to elucidating the nature 
of human autoimmune diseases is the protracted interval 
 between actual disease onset and overt expression. The 
NOD.c3c4 and NOD.c3c4-scid strains now provide the 
 opportunity to examine events at the very beginning of ABD. 
Moreover, the dissection of immunopathology of NOD.
c3c4 mice will include a congenic mapping strategy to deter-
mine the precise genetic regions necessary and suffi  cient for 
the disease process, analogous to the genetic dissection ongo-
ing in NOD mice (22). Comparison of the NOD.c3c4 with 
the genetically similar 1803 mouse demonstrates the sensitiv-
ity of the ABD process to quite minor changes in genetic 
make-up. A fundamental question is the causation of the 
“switch” from pancreatic islet to biliary tract in NOD and 
NOD.c3c4 mice, respectively, that are 95% genetically iden-
tical. The absence of ABD in strain 1803 suggests that the 
newly defi ned Abd1 region, which is independent of any 
known Idd locus, interacts with Idd loci on chromosome 3 to 
generate a completely diff erent autoimmune phenotype. 
Progressive reduction of the interval necessary for disease 
should reveal the identity of genes and their products that 
 orchestrate the remarkable switch from diabetes to ABD.
MATERIALS AND METHODS
Animals, tissue, and sera. NOD.c3c4, NOD, NOD-scid, and B6.H2g7 
(hereafter called B6.G7) mice were bred and housed under specifi c pathogen-
free conditions, and all procedures were conducted according to approved 
protocols of the University of Pittsburgh School of Medicine Animal Care 
and Use Committee. NOD.B6/10 Idd3/10/18R323 Idd9.1/9.2/9.3R905 
mice, hereafter designated strain 1803, were developed by intercrossing two 
established strains, NOD.B6 Idd3/10/18R323 and NOD.B10 Idd9.1/9.2/
9.3R905, and genotyping multiple markers within each segment to establish 
a strain that is homozygous for both introgressed regions. Line 1803 was bred 
and housed at Taconic under specifi c pathogen-free conditions. Stored sera 
were used from NOD.B10Idd9.1/9.2.9.3R28 (previously designated NOD.
c4a [reference 21] and called NOD.c4 here) and NOD.B6 Idd3/10/18R323 
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(previously designated NOD.c3a [reference 7] and called NOD.c3 here). 
The NOD.c4 strain and lines 1802 and 1803 are no longer extant. Strains 
NOD.c3c4, NOD.B6 Idd3/10/18R323, and NOD.B10 Idd9R905 are 
available as lines 1112, 1538, and 905 through the Emerging Models 
Program at Taconic. NOD.c3c4-scid mice were constructed as follows: 
NOD. 3c4 mice were mated to NOD-scid mice, and F1 mice were backcros-
sed to NOD.c3c4 mice. Progeny homozygous for the c3 and c4 intervals 
and  heterozygous for the scid mutation were intercrossed. The scid homozygous 
intercross progeny were identifi ed and became the founders of the NOD.
c3c4-scid line. Sera and tissues were collected between the ages of 0 and 60, 60 
and 100, 100 and 140, 140 and 200, and >200 d and stored at −80°C until use.
Liver histology. Liver tissues were immediately fi xed in 10% buff ered for-
malin, embedded in paraffi  n, and cut into 5-μm sections. Liver sections were 
deparaffi  nized, stained with hematoxylin and eosin, and evaluated micro-
scopically for leukocytic infi ltration. Eosinophils were defi ned by the pres-
ence of typical red granular cytoplasmic components in polynuclear cells. 
Immunohistochemical staining for CD3+ cells was performed using frozen 
tissues. In brief, liver sections were embedded in optimal cutting tempera-
ture compound (Tissue TEK) and frozen in liquid nitrogen. 5-μm-thick 
sections were cut with a cryostat, placed on 3-amino-propyltriethoxysilane–
coated slides, and fi xed in ice-cold acetone for 10 min. Slides were incubated 
in 0.3% H2O2, washed, and blocked with 10% goat serum in Protein Block 
(Immunon). The slides were then incubated with rat anti-CD3 1:100 (BD 
Biosciences) in a humidity chamber, washed with PBS, and incubated with 
biotinylated goat anti–rat (Jackson ImmunoResearch Laboratories). After 
washing, the slides were incubated with ABC (Vector Laboratories), washed, 
and incubated with AEC solution (Scytek). The slides were rinsed and coun-
terstained with aqueous hematoxylin blue. CD4+, CD8+, and DC2 cells 
were detected by biotin-conjugated CD4 (L3T4, clone RM4-5; eBiosci-
ence), CD8a (Ly-2, clone 53–6.7; eBioscience), and pDCA1 (clone JF05-
1C24.1; Miltenyi Biotec), respectively. After washing, the slides were 
incubated with ABC (Vector Laboratories), washed, incubated with diami-
nobenzidine (DakoCytomation), and counterstained with hematoxylin blue. 
Known positive and negative samples were incubated throughout, and opti-
mal dilutions of primary and secondary antibodies were used.
Preparation of splenocytes and HLCs. The spleen from each mouse was 
removed aseptically, and a single cell suspension was prepared. After lysing 
RBCs, the splenocytes were washed three times with PBS. HLCs were col-
lected after liver perfusion using Percoll density gradient centrifugation as 
described previously (23, 24). In brief, the liver was perfused postmortem 
with PBS via the portal vein, cut into small pieces, and pressed through wire 
mesh. After being washed with PBS, the cells were resuspended in 35% 
 Percoll solution (GE Healthcare) and centrifuged at 1,500 rpm for 30 min 
at room temperature. The pellet was resuspended in lysis solution to remove 
RBCs and washed twice in medium.
Cell purifi cation and stimulation. CD4+ or CD8+ cells were prepared by 
magnetic separation using a MiniMACS system (Miltenyi Biotec; reference 
25). In brief, splenocytes were incubated with anti-CD4 or anti-CD8 mag-
netic microbeads for 15 min, washed, and collected on a magnetic fl ow-
through column. Purifi ed cells were stimulated as described previously (25). 
In brief, cells were suspended in complete medium consisting of RPMI 1640 
supplemented with 10% (wt/vol) FCS, 1 mM l-alanyl-glutamine (Life Tech-
nologies), 100 U/ml penicillin, 100 μg/ml streptomycin (Life Technologies), 
1 mM sodium pyruvate (Life Technologies), and 50 μM 2-ME. Cells were 
then transferred to 24-well plates precoated with anti-CD3 antibody, and 
1 μg/ml anti-CD28 antibody (BD Biosciences) was added to each well. The 
cells were cultured for 72 h at 37°C in a humidifi ed 5% CO2 atmosphere. 
The supernatants were collected at the end of culture and stored at −80°C.
Cytokine measurement by ELISA. Cytokines (IFN-γ, IL-4, and IL-2) 
were measured by ELISA as described previously (25). In brief, a fl at-bottom 
96-well plate was coated with anti–IFN-γ, anti–IL-4, or anti–IL-2 antibodies 
(BD Biosciences) at 4°C overnight. Cell culture supernatants were added, 
and the plate was incubated for 2 h. After washing, the plate was incubated 
with biotinylated anti–IFN-γ, anti–IL-4, or anti–IL-2 antibodies (BD Bio-
sciences) for 1 h, and then washed and incubated for 1 h with europium-
 avidin solution (PerkinElmer). Enhancement solution (PerkinElmer) was 
added, and the europium fl uorescence was measured with a Victor 1420 
ELISA reader.
RNase protection assay. Total RNA was extracted from cultured cells 
using the RNeasy mini kit (QIAGEN). The RNA was re-dissolved in 
RNase-free water, and the yield was estimated by spectrophotometry. Equal 
quantities of RNA were used for analysis. RNase protection assay was per-
formed using RiboQuant (BD Biosciences) according to the manufacturer’s 
protocol. Multiprobe template set mCK-1 (containing templates for IL-4, 
IL-5, IL-10, IL-13, IL-15, IL-9, IL-2, IL-6, IF-, L32, and GAPDH) was 
purchased from BD Biosciences. The templates were used to synthesize the 
[-32P]UTP-labeled probes (3,000 Ci/mmol, 10 mCi/ml; NEN Life Science 
Products) in the presence of a GACU pool using a T7 RNA polymerase 
(BD Biosciences). Hybridization with 5–15 μg RNA was performed for 
12–14 h at 56°C, and the products were digested with an RNase A and T1 
mixture. The samples were treated by proteinase K in proteinase K buff er 
with yeast tRNA, extracted with phenol and chloroform/isoamyl alcohol 
(50:1), and precipitated in the presence of ammonium acetate. The samples 
were loaded on an acrylamide-urea gel and run at 40 W with 0.5× Tris-
 borate/EDTA electrophoresis buff er for 2 h. The gel was adsorbed to fi lter 
paper, vacuum dried, and exposed on fi lm (X-AR; Kodak) with intensifying 
screens at −70°C.
In vivo treatment with anti-CD3 antibody. 6–10-wk-old NOD.c3c4 
mice were treated with a single dose of 200 μg anti-CD3 antibody (145-
2C11), and control mice were treated with PBS alone. Mice were analyzed 
for disease and disease-related phenotypes 3 mo after treatment.
Flow cytometry. Antibodies against CD4, CD8, CD19, CD122, γδ TCR, 
CD69, T cell β receptor, and Gr-1 were purchased from BD Biosciences. 
Cells were incubated with Fc blocker (BD Biosciences) and stained with sat-
urating levels of labeled antibodies for 20 min at 4°C. Samples were analyzed 
on a FACSCalibur (Becton Dickinson).
Immunoreactivity to mitochondria and epitope specifi city analysis. 
Immunoreactivity of serum samples to the major mitochondrial antigen, 
PDC-E2, was studied by immunoblotting as described previously (26). In 
brief, 20 μg recombinant protein was resolved by SDS-PAGE, transferred 
onto nitrocellulose membranes, blocked with 3% nonfat dry milk in PBS, 
and probed with sera from NOD.c3c4 and control mice (1:200 dilution) for 
1 h. After three 5-min washes with PBS/0.05% Tween-20, the membranes 
were incubated with horseradish peroxidase–conjugated anti–mouse IgG 
(Zymed Laboratories), washed with PBS/0.05% Tween-20, and developed 
by chemiluminescence. Known positive mAb to PDC-E2 (27) was used as a 
positive control. To determine the specifi c PDC-E2 epitope recognized, re-
combinant PDC-E2 outer lipoyl domain, inner lipoyl domain, E1/E3 bind-
ing site, and the catalytic domain were resolved on 10% SDS-PAGE, transferred 
to nitrocellulose membranes, and probed with AMA+ serum samples and 
developed as described above.
PDC enzyme inhibition assay. To determine if NOD.c3c4 sera inhibit 
PDC enzyme activity, sera (1:100) from 7-mo-old NOD.c3c4 mice were 
incubated with purifi ed PDC (Sigma-Aldrich) for 10 min at room tempera-
ture and added to a mixture containing 5 mM sodium pyruvate, 2.5 mM 
NAD+, 0.2 mM thiamine pyrophosphate, 0.1 mM coenzyme A, 0.3 mM 
dithiothreitol, 1 mM magnesium chloride, and 50 mM potassium phosphate 
buff er, pH 8.0. Changes in absorbency per minute at 340 nm were moni-
tored for 5 min. Inhibition of PDC enzyme activity by serum samples from 
control NOD mice, human PBC patients, and healthy human control 
 human sera were analyzed in parallel using 6 sera/group. Enzyme activity 
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without sera was determined in parallel, and the values were defi ned as 
100% activity.
Statistical analysis. Diff erences between groups were analyzed using the 
Mann-Whitney test. Contingency analyses were performed by Fisher’s and 
Chi squared tests.
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